NASDAQ:IRWD Ironwood Pharmaceuticals (IRWD) Stock Price, News & Analysis $4.06 +0.13 (+3.31%) (As of 09/26/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Ironwood Pharmaceuticals alerts: Email Address About Ironwood Pharmaceuticals Stock (NASDAQ:IRWD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get IRWD alerts:Sign Up Key Stats Today's Range$3.88▼$4.0850-Day Range$3.93▼$7.0452-Week Range$3.79▼$15.70Volume1.03 million shsAverage Volume3.22 million shsMarket Capitalization$635.51 millionP/E RatioN/ADividend YieldN/APrice Target$13.57Consensus RatingModerate Buy Company OverviewIronwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.Read More… FDA’s hidden signal greenlights biotech winners — 97% of the time (Ad)The FDA has started to quietly send out a signal … That has given investors a 97% chance of making money. Perhaps as soon as 9:30 a.m. tomorrow. Click here to find out how you can get in before the FDA’s potential signal. Ironwood Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks96th Percentile Overall ScoreIRWD MarketRank™: Ironwood Pharmaceuticals scored higher than 96% of companies evaluated by MarketBeat, and ranked 51st out of 995 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingIronwood Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageIronwood Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ironwood Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth37.50% Earnings GrowthEarnings for Ironwood Pharmaceuticals are expected to grow by 37.50% in the coming year, from $0.24 to $0.33 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ironwood Pharmaceuticals is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ironwood Pharmaceuticals is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Ironwood Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.46% of the float of Ironwood Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverIronwood Pharmaceuticals has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Ironwood Pharmaceuticals has recently decreased by 14.63%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIronwood Pharmaceuticals does not currently pay a dividend.Dividend GrowthIronwood Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG3.4 / 5Environmental Score-2.94 Percentage of Shares Shorted7.46% of the float of Ironwood Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverIronwood Pharmaceuticals has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Ironwood Pharmaceuticals has recently decreased by 14.63%, indicating that investor sentiment is improving significantly. News and Social Media2.8 / 5News Sentiment1.09 News SentimentIronwood Pharmaceuticals has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Ironwood Pharmaceuticals this week, compared to 4 articles on an average week. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ironwood Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $42,316.00 in company stock.Percentage Held by Insiders12.90% of the stock of Ironwood Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Ironwood Pharmaceuticals' insider trading history. Receive IRWD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ironwood Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address IRWD Stock News HeadlinesIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Average Recommendation of "Moderate Buy" by BrokeragesSeptember 23 at 5:14 AM | americanbankingnews.comIRWD Dec 2024 7.500 putSeptember 22, 2024 | ca.finance.yahoo.com[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.September 26, 2024 | Paradigm Press (Ad)Ironwood Pharmaceuticals (NASDAQ:IRWD) versus Helix BioPharma (OTCMKTS:HBPCF) Head-To-Head SurveySeptember 18, 2024 | americanbankingnews.comLeerink Partners Initiates Coverage of Ironwood Pharmaceuticals (IRWD) with Market Perform RecommendationSeptember 9, 2024 | msn.comIronwood Pharmaceuticals, Inc. (IRWD): The Best Multibagger Penny Stock of 2025?September 2, 2024 | insidermonkey.comIronwood Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare ConferenceAugust 31, 2024 | finance.yahoo.comAnalysts Have Just Cut Their Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Revenue Estimates By 13%August 15, 2024 | finance.yahoo.comSee More Headlines IRWD Stock Analysis - Frequently Asked Questions How have IRWD shares performed this year? Ironwood Pharmaceuticals' stock was trading at $11.44 on January 1st, 2024. Since then, IRWD shares have decreased by 64.5% and is now trading at $4.06. View the best growth stocks for 2024 here. How were Ironwood Pharmaceuticals' earnings last quarter? Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) issued its quarterly earnings results on Thursday, May, 9th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.18 by $0.20. The business's revenue for the quarter was down 28.0% on a year-over-year basis. Who are Ironwood Pharmaceuticals' major shareholders? Ironwood Pharmaceuticals' top institutional investors include Pacer Advisors Inc. (5.69%), Renaissance Technologies LLC (5.48%), Armistice Capital LLC (4.98%) and LSV Asset Management (3.88%). Insiders that own company stock include Thomas A Mccourt, Mark G Currie, Jason Rickard, Michael Shetzline, Sravan Kumar Emany, Minardo John, Andrew Davis, Julie Mchugh, Jon R Duane, Ronald Silver, Catherine Moukheibir and Marla L Kessler. View institutional ownership trends. How do I buy shares of Ironwood Pharmaceuticals? Shares of IRWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Ironwood Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ironwood Pharmaceuticals investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), NIC (EGOV), Athabasca Oil (ATH) and Allergan (AGN). Company Calendar Last Earnings5/09/2024Today9/26/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:IRWD CUSIP46333X10 CIK1446847 Webwww.ironwoodpharma.com Phone(617) 621-7722Fax617-494-0480Employees220Year FoundedN/APrice Target and Rating Average Stock Price Target$13.57 High Stock Price Target$22.00 Low Stock Price Target$4.00 Potential Upside/Downside+249.8%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($6.79) Trailing P/E RatioN/A Forward P/E Ratio16.17 P/E GrowthN/ANet Income$-1,002,240,000.00 Net Margins2.30% Pretax Margin21.50% Return on Equity-6.37% Return on Assets4.61% Debt Debt-to-Equity RatioN/A Current Ratio3.92 Quick Ratio3.92 Sales & Book Value Annual Sales$442.73 million Price / Sales1.40 Cash FlowN/A Price / Cash FlowN/A Book Value($2.21) per share Price / Book-1.76Miscellaneous Outstanding Shares159,740,000Free Float136,337,000Market Cap$619.79 million OptionableOptionable Beta0.49 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:IRWD) was last updated on 9/26/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredWhat I believe the Bible says about investing..Greed leads to lying, cheating and stealing to fill an endless appetite for more. And as my friend and trus...Prosperity Research | SponsoredThe Great AI Election of 2024Former House Speaker Nancy Pelosi made 20 times her salary trading Nvidia (NVDA) stock. A recent report out...Chaikin Analytics | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredFed Triggers Boom: Buy this Play on Elon’s New AIHave you seen Elon Musk's new invention? I was already very bullish on this new type of AI. And now that...InvestorPlace | SponsoredAmerica’s new currency (check your wallet)A new currency could soon start circulating all over America. It's already being issued by certain major fi...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ironwood Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ironwood Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IRWD Stock Alerts